reports
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approxima...
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidanceSuccessfully repaid term loan to Morgan Stanley Tactical Value, further simplifying the Company’s capital structurePhase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) remains on track to begin in 3Q 2025Cash runway extended into 2028 SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today a...
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investme...
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will deliver a company presentation on Tuesday, September 9 at 12:00 PM ET at the Lotte New York Palace Hotel. A live webcast of the presentation will be available . FibroGen’s management team will b...
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca b...
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025. The closing of the transaction remains subject to other contractual closing conditions and del...
FibroGen Reports Second Quarter 2025 Financial Results and Provides Bu...
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2028 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant...
FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat...
FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes FibroGen has reached agreement with the FDA on important design elements for a pivotal Phase 3 clinical trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell (RBC) transfusion burdenCompany intends to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive f...
FibroGen to Report Second Quarter 2025 Financial Results
FibroGen to Report Second Quarter 2025 Financial Results SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business up...
Fibrogen Inc: 1 director
A director at Fibrogen Inc bought 23,567 shares at 5.070USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
FibroGen Announces 1-for-25 Reverse Stock Split
FibroGen Announces 1-for-25 Reverse Stock Split SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. FibroGen’s common stock will begin trading on a split-adjusted basis on June 17, 2025, when the markets open, under the Company’s existing trading symbol “FGEN,” with the new CUSIP number 31572Q881. The Reverse Stock Split was previously approved by stockholders at the Compa...
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Direct...
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025. “Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board,” said James Schoeneck, chairman of the board of directors of FibroGen. “His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michael’s deep understanding o...
FibroGen Reports First Quarter 2025 Financial Results and Provides Bus...
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $100 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2H 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-r...
FibroGen to Report First Quarter 2025 Financial Results
FibroGen to Report First Quarter 2025 Financial Results SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. ...
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare ...
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. FibroGen’s management team will be available for one-on-one meetings on Wednesday, April 9th. Interested investors should contact their representative at Needham. About FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer bi...
- Jonathan Moreland
WYNN WYNN RESORTS LIMITED
ULTA ULTA BEAUTY INC
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TITN TITAN MACHINERY
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
OMCL OMNICELL INC.
MG MISTRAS GROUP
MEI METHODE ELECTRONICS INC.
MCHX MARCHEX INC. CL B
IMMR IMMERSION CORP.
HSC HARSCO CORPORATION
GOGO GOGO INC.
GCO GENESCO INC.
FGEN FIBROGEN INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
AHH ARMADA HOFFLER PROPERTIES INC.
ADBE ADOBE INC.
OPRX OPTIMIZERX CORP
QRHC QUEST RESOURCE HOLDING
DRTTF DIRTT ENVIRONMENTAL SOLUTIONS
ECC EAGLE POINT CREDIT CO INC
GCBC GREENE COUNTY BANCORP INC.
HI HILLENBRAND INC.
LIVE LIVE VENTURES
BV BRIGHTVIEW HOLDINGS
HFFG HF FOODS GROUP INC
TROX TRONOX HOLDINGS PLC
AEYE AUDIOEYE INC
ZYME ZYMEWORKS INC.
GRWG GROWGENERATION
PRLD PRELUDE THERAPEUTICS
FTHM FATHOM HOLDINGS
IMNM IMMUNOME
LYEL LYELL IMMUNOPHARMA INC
TOI ONCOLOGY INSTITUTE INC (THE)
HD HOME DEPOT
BTMD INC.
BLIN HAYMAKER ACQUISITION CORP III
BUKS BRIDGELINE DIGITAL INC
MODD BUTLER NATIONAL CORP
MLYS MODULAR MEDICAL INC
WEST MINERALYS THERAPEUTICS INC
SRFM WESTROCK COFFEE COMPANY LLC
GUTS SURF AIR MOBILITY INC.
ADVM FRACTYL HEALTH INC
AFCG ADVERUM BIOTECHNOLOGIES INC.
FG AFC GAMMA
EU INC.
F AND G ANNUITIES AND LIFE
INC.
WISDOMTREE EURO DEBT FUND
FibroGen Announces Publication of Results from Phase 1 Monotherapy Stu...
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancerInitiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC expected by mid-2025 SAN FRANCISCO, March 28, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the peer-reviewed publication titled in the Journal of Clinical Onc...
- Jonathan Moreland
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway extended into 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected by mid-2025 Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination w...
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial resul...
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Appro...
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 millionUpon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company’s capital structure Company’s cash runway extended into 2027 Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer ...
FibroGen Appoints David DeLucia as Chief Financial Officer
FibroGen Appoints David DeLucia as Chief Financial Officer SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen’s global finance organization. He has most recently served as FibroGen’s Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and ...
FibroGen Reports Third Quarter 2024 Financial Results
FibroGen Reports Third Quarter 2024 Financial Results Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) are expected in 1H 2025Initiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC anticipated in 1Q 2025Third quarter net revenue growth of 15% year over year, driven by strong performance of roxadustat in China, with year over year volume growth of 34% Reiterate full ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.